Regmi Parbatraj, Hu Hai-Jie, Paudyal Pranita, Liu Fei, Ma Wen-Jie, Yin Chang-Hao, Jin Yan-Wen, Li Fu-Yu
Department of Biliary Surgery, West China Hospital, Sichuan University, Chengdu, 610041, Sichuan Province, China.
Eur J Surg Oncol. 2021 May;47(5):979-989. doi: 10.1016/j.ejso.2020.11.310. Epub 2020 Dec 7.
The use of laparoscopic liver resection for curative surgery of intrahepatic cholangiocarcinoma (ICC) is not well established. Herein, we perform a meta-analysis to compare the differences between laparoscopic liver resection (LLR) and open liver resection (OLR) for ICC.
Multiple electronic databases were searched and 8 relevant studies containing 552 patients treated by LLR and 2320 treated by OLR were identified. The fixed effects and a random-effects model were used to perform a meta-analysis.
Compared with OLR, LLR for ICC was associated with less blood transfusion (7.14% versus 17.11%; OR: 0.32; 95% CI 0.15 to 0.71; P < 0.05), higher R0 resection (85.63% versus 74.69%; OR: 1.48; 95% CI 1.13 to 1.95; P < 0.05), shorter length of stay (LOS) (SMD: -0.40; 95% CI -0.80 to 0.00; P = 0.05), less overall morbidities (20% versus 32.69%; OR: 0.50; 95% CI 0.33 to 0.78; P < 0.05), and less death due to tumor recurrence (22.39% versus 35.48%; OR: 0.50; 95% CI 0.29 to 0.86; P <0.05); but LLR was associated with smaller ICC, fewer major hepatectomies, less lymph node (LN) dissection rate, and inferior 5-year overall survival (OS) (P < 0.05). Duration of operation, blood loss, average LN retrieved, LN metastasis, major morbidities, mortality, tumor recurrence, 3-year OS and disease free survival (DFS), and 5-year DFS were comparable (P >0.05).
LLR for ICC is in the initial phase of exploration. More evidence is necessary to validate LLR for ICC.
腹腔镜肝切除术用于肝内胆管癌(ICC)根治性手术的应用尚未得到充分确立。在此,我们进行一项荟萃分析,以比较腹腔镜肝切除术(LLR)和开腹肝切除术(OLR)治疗ICC的差异。
检索多个电子数据库,确定了8项相关研究,其中552例患者接受LLR治疗,2320例患者接受OLR治疗。采用固定效应模型和随机效应模型进行荟萃分析。
与OLR相比,LLR治疗ICC的输血率较低(7.14%对17.11%;OR:0.32;95%CI 0.15至0.71;P<0.05),R0切除率较高(85.63%对74.69%;OR:1.48;95%CI 1.13至1.95;P<0.05),住院时间较短(SMD:-0.40;95%CI -0.80至0.00;P = 0.05),总体并发症较少(20%对32.69%;OR:0.50;95%CI 0.33至0.78;P<0.05),肿瘤复发导致的死亡较少(22.39%对35.48%;OR:0.50;95%CI 0.29至0.86;P<0.05);但LLR与较小的ICC、较少的肝大部切除术、较低的淋巴结清扫率以及较差的5年总生存率(OS)相关(P<0.05)。手术时间、失血量、平均获取的淋巴结、淋巴结转移、主要并发症、死亡率、肿瘤复发、3年OS和无病生存率(DFS)以及5年DFS相当(P>0.05)。
LLR治疗ICC尚处于探索初期。需要更多证据来验证LLR治疗ICC的效果。